<VariationArchive RecordType="classified" VariationID="13814" VariationName="NM_000168.6(GLI3):c.2023del (p.Glu675fs)" VariationType="Deletion" Accession="VCV000013814" Version="3" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2022-04-25" DateCreated="2015-05-23" MostRecentSubmission="2015-05-23">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="28853" VariationID="13814">
      <GeneList>
        <Gene Symbol="GLI3" FullName="GLI family zinc finger 3" GeneID="2737" HGNC_ID="HGNC:4319" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>7p14.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="7" Accession="NC_000007.14" start="41960949" stop="42264268" display_start="41960949" display_stop="42264268" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="7" Accession="NC_000007.13" start="42000546" stop="42276617" display_start="42000546" display_stop="42276617" Strand="-" />
          </Location>
          <OMIM>165240</OMIM>
          <Haploinsufficiency last_evaluated="2021-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GLI3">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GLI3">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_000168.6(GLI3):c.2023del (p.Glu675fs)</Name>
      <CanonicalSPDI>NC_000007.14:41972416:C:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>7p14.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="7" Accession="NC_000007.14" start="41972417" stop="41972417" display_start="41972417" display_stop="41972417" variantLength="1" positionVCF="41972416" referenceAlleleVCF="TC" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="7" Accession="NC_000007.13" start="42012016" stop="42012016" display_start="42012016" display_stop="42012016" variantLength="1" positionVCF="42012015" referenceAlleleVCF="TC" alternateAlleleVCF="T" />
      </Location>
      <ProteinChange>E675fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000007.13" sequenceAccession="NC_000007" sequenceVersion="13" change="g.42012016del" Assembly="GRCh37">
            <Expression>NC_000007.13:g.42012016del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000007.14" sequenceAccession="NC_000007" sequenceVersion="14" change="g.41972417del" Assembly="GRCh38">
            <Expression>NC_000007.14:g.41972417del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008434.1" sequenceAccession="NG_008434" sequenceVersion="1" change="g.269603del">
            <Expression>NG_008434.1:g.269603del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000168.6" sequenceAccession="NM_000168" sequenceVersion="6" change="c.2023del" MANESelect="true">
            <Expression>NM_000168.6:c.2023del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000159.3" sequenceAccession="NP_000159" sequenceVersion="3" change="p.Glu675fs">
            <Expression>NP_000159.3:p.Glu675fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA341301" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="165240.0002" DB="OMIM" />
        <XRef Type="rs" ID="116840744" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000168.6(GLI3):c.2023del (p.Glu675fs) AND Pallister-Hall syndrome" Accession="RCV000014825" Version="30">
        <ClassifiedConditionList TraitSetID="3814">
          <ClassifiedCondition DB="MedGen" ID="C0265220">Pallister-Hall syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="1997-03-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="1997-03-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2015-05-23" MostRecentSubmission="2015-05-23">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">9054938</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3814" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3351" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Hypothalamic hamartoblastoma, hypopituitarism, imperforate anus, and postaxial polydactyly</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Pallister-Hall syndrome</ElementValue>
                <XRef ID="Pallister-Hall+syndrome/5543" DB="Genetic Alliance" />
                <XRef ID="MONDO:0007804" DB="MONDO" />
                <XRef ID="56677004" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PHS</ElementValue>
                <XRef Type="MIM" ID="146510" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">PHS1</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Pallister-Hall syndrome (referred to as PHS in this entry) is characterized by a spectrum of anomalies ranging from polydactyly, asymptomatic bifid epiglottis, and hypothalamic hamartoma at the mild end to laryngotracheal cleft with neonatal lethality at the severe end. Individuals with mild PHS may be incorrectly diagnosed as having isolated postaxial polydactyly type A. Individuals with PHS can have pituitary insufficiency and may die as neonates from undiagnosed and untreated adrenal insufficiency.</Attribute>
                <XRef ID="NBK1465" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7305" />
                <XRef ID="7305" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301638</ID>
                <ID Source="BookShelf">NBK1465</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301753</ID>
                <ID Source="BookShelf">NBK5192</ID>
              </Citation>
              <XRef ID="672" DB="Orphanet" />
              <XRef ID="C0265220" DB="MedGen" />
              <XRef ID="MONDO:0007804" DB="MONDO" />
              <XRef Type="MIM" ID="146510" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="35080" SubmissionDate="2015-05-21" DateLastUpdated="2015-05-23" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="165240.0002_PALLISTER-HALL SYNDROME" title="GLI3, 1-BP DEL, 2023G_PALLISTER-HALL SYNDROME" />
        <ClinVarAccession Accession="SCV000035080" DateUpdated="2015-05-23" DateCreated="2013-04-04" Type="SCV" Version="4" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1997-03-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In the exons spanning nucleotides 1813-2103 of the GLI3 cDNA, Kang et al. (1997) found by SSCP analysis a different abnormal band in affected members of each of 2 families with Pallister-Hall syndrome (PHS; 146510). In 1 family, the de novo mutation originating the disorder was identified. One family showed a 1-bp deletion (2023G) that predicted a frameshift and premature stop 16 codons 3-prime of the mutation. In a second family they found that 3 affected members were heterozygous for a single-base deletion involving 2012G (165240.0003). This deletion resulted in a frameshift and predicted protein termination codon in the same location as that in the other family. The mutations predicted a protein truncated after 691 amino acids, compared to the predicted length of 1,596 amino acids for the normal gene product. These mutant alleles terminate just C-terminal of the zinc finger domains, with 16-20 residues of abnormal protein sequence between the frameshift and the stop codon.</Attribute>
              <Citation>
                <ID Source="PubMed">9054938</ID>
              </Citation>
              <XRef DB="OMIM" ID="146510" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLI3" />
          </GeneList>
          <Name>GLI3, 1-BP DEL, 2023G</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">1-BP DEL, 2023G</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="165240.0002" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">PALLISTER-HALL SYNDROME</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="35080" TraitType="Disease" MappingType="Name" MappingValue="PALLISTER-HALL SYNDROME" MappingRef="Preferred">
        <MedGen CUI="C0265220" Name="Pallister-Hall syndrome" />
      </TraitMapping>
    </TraitMappingList>
    <DeletedSCVList>
      <SCV>
        <Accession Version="1" DateDeleted="2022-03-15">SCV000054471</Accession>
        <Description>This variant is no longer cited in the GeneReview and has been deleted.</Description>
      </SCV>
    </DeletedSCVList>
  </ClassifiedRecord>
</VariationArchive>

